E-cadherin基因启动子区甲基化与肺癌易感性的meta分析研究

摘要

背景与目的 上皮细胞钙粘蛋白E-cadherin在维持上皮的极性和结构完整性等方面起着重要作用,并与肿瘤的发生、浸润和转移密切相关.E-cadherin基因启动子区甲基化与肿瘤发生发展的关系一直是研究的热点,而该基因甲基化与肺癌易感性的关系尚存在争议.本研究旨在通过meta分析的方法更好地探讨E-cadherin基因启动子区甲基化与肺癌易感性之间的关系.方法 利用PubMed/MedLine和EMBASE数据库检索2013年3月以前的相关文献,由两位研究人员做独立文献筛选和资料提取,并交叉审核.使用优势比(odds ratio,OR)及95％置信区间(confidence interval,CI)衡量E-cadherin基因启动子区甲基化与肺癌易感性关系的强弱.结果 根据检索条件,共有13项研究(共涉及1,288例实验样本)被纳入当前的meta分析.分析结果显示E-cadherin基因启动子区甲基化明显增加了肺癌发生风险(OR=4.04,95％CI:200-8.13,P＜0.001),且这种相关性同时存在于亚洲人群和高加索人群(OR=3.28,95％CI:1.20-8.92;OR=5.72,95％CI:2.40-13.62).结论 E-cadherin基因启动子区甲基化与肺癌易感性之间存在明显相关性.%Background and objective As a member of the cadherin superfamily,E-cadherin plays a critical role in the maintenance of cell polarity and integrity.And E-cadherin was reported to be down-regulated and dosely related to tumor initiation,invasion and metastasis.There have been a number of studies investigating the methylation of E-cadherin promoter in relation to various cancers.However,the association between E-cadherin promoter methylation and lung cancer risk is controversial.The aim of the present study is to evaluate the association of E-cadherin promoter methylation with risk of lung cancer by conducting a systematic meta-analysis.Methods Relevant studies were identified by searches of PubMed/MedLine and EMBASE databases before March 2013.Combined odds ratio (OR) and 95％ confidence interval (CI) were used to assess the strength of the association between E-cadherin promoter methylation and lung cancer risk.Results A total of 1,288 samples from 13 independent studies were included in the meta-analysis.Overall,a significant association was observed between E-cadherin promoter methylation and lung cancer risk (OR=4.04,95％CI:2.00-8.13,P＜0.001).Subgroup analyses by ethnic revealed that lung cancer risk was increased for individuals carrying the methylated E-cadherin in Asian and Caucasian populations (OR=3.28,95％CI:1.20-8.92;OR=5.72,95％CI:2.40-13.62).Conclusion The present meta-analysis indicates that the methylation of E-cadherin promoter is associated with risk of lung cancer.